Biogen Inc. [NASDAQ: BIIB] surged by $109.71 during the normal trading session on Monday and reaching a high of $468.55 during the day while it closed the day at $395.85. The company report on June 7, 2021 that Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™.
Programs now available to support patients and families with their treatment journey.
Collaborations with Veterans Health Administration, CVS Health and NAFC focused on health disparities in underserved communities.
Biogen Inc. stock has also gained 47.99% of its value over the past 7 days. However, BIIB stock has inclined by 46.61% in the 3 months of the year. Over the past six months meanwhile, it has gained 62.17% and gained 61.66% year-on date.
The market cap for BIIB stock reached $56.76 billion, with 151.90 million shares outstanding and 149.58 million shares in the current float. Compared to the average trading volume of 1.12M shares, BIIB reached a trading volume of 17815413 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Biogen Inc. [BIIB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BIIB shares is $287.87 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BIIB stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Biogen Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on June 07, 2021. While these analysts kept the previous recommendation, Cowen raised their target price from $225 to $450. The new note on the price target was released on June 07, 2021, representing the official price target for Biogen Inc. stock. Previously, the target price had yet another raise from $235 to $400, while BofA Securities kept a Neutral rating on BIIB stock.
The Average True Range (ATR) for Biogen Inc. is set at 19.90, with the Price to Sales ratio for BIIB stock in the period of the last 12 months amounting to 4.50. The Price to Book ratio for the last quarter was 5.63, with the Price to Cash per share for the same quarter was set at 17.70. Price to Free Cash Flow for BIIB in the course of the last twelve months was 16.51 with Quick ratio for the last quarter at 1.80.
BIIB stock trade performance evaluation
Biogen Inc. [BIIB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 47.99. With this latest performance, BIIB shares gained by 45.47% in over the last four-week period, additionally plugging by 62.17% over the last 6 months – not to mention a rise of 32.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIIB stock in for the last two-week period is set at 89.15, with the RSI for the last a single of trading hit 93.26, and the three-weeks RSI is set at 85.05 for Biogen Inc. [BIIB]. The present Moving Average for the last 50 days of trading for this stock 275.16, while it was recorded at 298.21 for the last single week of trading, and 268.27 for the last 200 days.
Biogen Inc. [BIIB]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Biogen Inc. [BIIB] shares currently have an operating margin of +30.76 and a Gross Margin at +81.69. Biogen Inc.’s Net Margin is presently recorded at +32.38.
Return on Total Capital for BIIB is now 19.80, given the latest momentum, and Return on Invested Capital for the company is 21.78. Return on Equity for this stock inclined to 33.28, with Return on Assets sitting at 15.43. When it comes to the capital structure of this company, Biogen Inc. [BIIB] has a Total Debt to Total Equity ratio set at 73.94. Additionally, BIIB Total Debt to Total Capital is recorded at 42.51, with Total Debt to Total Assets ending up at 32.14. Long-Term Debt to Equity for the company is recorded at 73.16, with the Long-Term Debt to Total Capital now at 42.06.
Reflecting on the efficiency of the workforce at the company, Biogen Inc. [BIIB] managed to generate an average of $439,626 per employee. Receivables Turnover for the company is 5.15 with a Total Asset Turnover recorded at a value of 0.48.Biogen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.10.
Earnings per share (EPS) analysis for Biogen Inc. [BIIB] stock
With the latest financial reports released by the company, Biogen Inc. posted 10.26/share EPS, while the average EPS was predicted by analysts to be reported at 8.03/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 27.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIIB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biogen Inc. go to -12.33%.
Biogen Inc. [BIIB]: Insider Ownership positions
There are presently around $50,557 million, or 86.90% of BIIB stock, in the hands of institutional investors. The top three institutional holders of BIIB stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 16,758,256, which is approximately 5.917% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 13,502,628 shares of the stock with an approximate value of $5.35 billion in BIIB stocks shares; and VANGUARD GROUP INC, currently with $4.69 billion in BIIB stock with ownership of nearly -0.36% of the company’s market capitalization.
Positions in Biogen Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 496 institutional holders increased their position in Biogen Inc. [NASDAQ:BIIB] by around 8,573,073 shares. Additionally, 516 investors decreased positions by around 10,017,901 shares, while 185 investors held positions by with 109,126,950 shares. The mentioned changes placed institutional holdings at 127,717,924 shares, according to the latest SEC report filing. BIIB stock had 139 new institutional investments in for a total of 2,056,827 shares, while 109 institutional investors sold positions of 1,175,459 shares during the same period.